Table 2.

NEC patients’ characteristics.

Characteristics	All Patients (n = 30)
Sex, female	12 (40%)
Age at initial diagnosis, median (years)	49 (26–71)
Comorbidities
Diabetes	n = 3 (27%)
Arterial hypertension	n = 3 (27%)
Primary tumor localization
Pancreas	n = 14 (47%)
Ileum	n = 2 (6%)
Stomach	n = 7 (23%)
Other:	n = 7 (23%)
Rectum	n= 2
Thymus	n = 1
Lung	n = 1
Larynx	n = 1
Cortex of suprarenal gland	n = 1
CUP	n = 1
Median survival (months), range	n = 123 (0–176)
No. of patients alive	n = 11 (37%)
No. of death patients	n = 7 (23%)
No. of patients lost-to-follow-up	n = 12 (40%)
Metastases	n = 20
Hepatic metastases	n = 20 (20/24; 83%)
Lymph node metastases	n = 16 (16/25; 64%)
Bone metastases	n = 6 (6/22; 27%)
Peritoneal carcinomatosis	n = 7 (7/22; 32%)
Grading:	n = 29
G1	n = 0
G2	n = 2 (7%)
G3	n = 25 (93%)
Ki-67 (%), median (range)	28 (20–95)
Ki-67 ≤ 20	n = 8 (36%)
Ki-67 >20	n = 14 (64%)
T stage	n = 9
T1	n = 0
T2	n = 2 (22%)
T3	n= 3 (33%)
T4	n = 4 (44%)
Relapse
no	n = 19 (95%)
yes	n = 1 (5%)
Functional disease
no	n = 16 (80%)
yes	n = 4 (20%)
SSR expression	n = 22
no	n = 16 (73%)
yes	n = 6 (27%)
Creatinine (mg/dL), median; (range)	0.85; (0.52–1.60)
Creatine < 1	n = 21 (81%)
Creatine ≥ 1	n = 5 (19%)
Chromogranin A (μg/L), median; (range)	138 (1–454)
<137 μg/L	n = 4 (50%)
≥137 μg/L	n = 4 (50%)

NEC, neuroendocrine carcinomas; CUP, cancer of unknown primary; SSR, somatostatin receptor.